ES2104339T3 - Nuevas particulas proteinicas. - Google Patents

Nuevas particulas proteinicas.

Info

Publication number
ES2104339T3
ES2104339T3 ES94902961T ES94902961T ES2104339T3 ES 2104339 T3 ES2104339 T3 ES 2104339T3 ES 94902961 T ES94902961 T ES 94902961T ES 94902961 T ES94902961 T ES 94902961T ES 2104339 T3 ES2104339 T3 ES 2104339T3
Authority
ES
Spain
Prior art keywords
sequence
amino acids
new protein
protein particles
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94902961T
Other languages
English (en)
Inventor
Sally Elizabeth Adams
Robert Nigel Burns
Simon Mark Harold Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Biotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharmaceuticals Ltd filed Critical British Biotech Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2104339T3 publication Critical patent/ES2104339T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UNA PROTEINA NO NATURAL FORMADORA DE PARTICULAS COMPRENDE UN AUTOENSAMBLAJE DE UNA PRIMERA SECUENCIA DE AMINOACIDOS FORMADORES DE PARTICULAS SUBSTANCIALMENTE HOMOLOGOS CON UN RETRANSMISOR DE PROTEINA DE LEVADURA TY PL Y UNA SEGUNDA SECUENCIA DE AMINOACIDOS, EN LA QUE LA SEGUNDA SECUENCIA ES ANTIGENICA Y ESTA INCORPORADA EN UN EPITOPO A PARTIR DE LA PRIMERA SECUENCIA DE AMINOACIDOS, DICHO EPITOPO FORMADO AISLADAMENTE EN PARTICULAS A PARTIR DE LA PRIMERA SECUENCIA DE AMINOACIDOS, ESTA EXPUESTO A LA SUPERFICIE.
ES94902961T 1992-12-29 1993-12-24 Nuevas particulas proteinicas. Expired - Lifetime ES2104339T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929227068A GB9227068D0 (en) 1992-12-29 1992-12-29 Novel proteinaceous particles

Publications (1)

Publication Number Publication Date
ES2104339T3 true ES2104339T3 (es) 1997-10-01

Family

ID=10727292

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94902961T Expired - Lifetime ES2104339T3 (es) 1992-12-29 1993-12-24 Nuevas particulas proteinicas.

Country Status (9)

Country Link
US (1) US6060064A (es)
EP (1) EP0677111B1 (es)
JP (1) JPH08505768A (es)
AT (1) ATE153071T1 (es)
AU (1) AU5711294A (es)
DE (1) DE69310768T2 (es)
ES (1) ES2104339T3 (es)
GB (1) GB9227068D0 (es)
WO (1) WO1994014969A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
US20080233181A1 (en) * 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
DK1524994T3 (da) 2002-07-19 2011-08-15 Cytos Biotechnology Ag Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
KR20050115913A (ko) 2003-03-26 2005-12-08 사이토스 바이오테크놀로지 아게 Ｍｅｌａｎ―ａ 펩티드 유사체-바이러스-양-입자컨쥬게이트
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc HETERO DUPLEX TRACKING TEST
JP2010508860A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
CN102014874A (zh) 2008-03-04 2011-04-13 流体科技公司 免疫调节剂颗粒和治疗方法
WO2010025425A1 (en) 2008-08-29 2010-03-04 Angros Lee H Multiplexed microscope slide staining apparatus
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering

Also Published As

Publication number Publication date
GB9227068D0 (en) 1993-02-24
DE69310768T2 (de) 1997-12-04
EP0677111B1 (en) 1997-05-14
ATE153071T1 (de) 1997-05-15
WO1994014969A1 (en) 1994-07-07
EP0677111A1 (en) 1995-10-18
JPH08505768A (ja) 1996-06-25
AU5711294A (en) 1994-07-19
DE69310768D1 (de) 1997-06-19
US6060064A (en) 2000-05-09

Similar Documents

Publication Publication Date Title
ES2104339T3 (es) Nuevas particulas proteinicas.
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
DE69425699D1 (de) Integrierung von Systemverwaltungsdiensten mit einem unterliegenden Systemobjektmodell
EA199700126A1 (ru) Вакцина против гепатита в
ES2124276T3 (es) Anticuerpos perfeccionados contra plasmodium falciparum.
DE3856496T2 (de) Hepatitis-B-Oberflächenantigen enthaltendes Peptid
HK1012841A1 (en) Pharmaceutical composition for the treatment or prevention of amalignant tumor
ATE159727T1 (de) Kleinste erkennungseinheit eines pem-mucin- ''tandem repeat''-spezifischen monoklonalen antikoerpers
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
KR900700507A (ko) Htlv-1 감염 검출용 합성 펩티드 항원
AU616156B2 (en) Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
ATE193208T1 (de) Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen
DE69126577D1 (de) Antigenes Peptid zum Nachweis von Anti-Hepatitis-C-Virus-Antikörpern und dessen Verwendung
SE8500712D0 (sv) Peptidforening samt antiserum framstellt med anvendning av denna forening
AR246856A1 (es) Un metodo para producir extractos de levadura, extracto de levadura producido mediante dicho metodo.
ZA943920B (en) Pharmaceutical compositions
CA2178635A1 (en) Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
ATE31418T1 (de) Arzneimittel, welche tripeptide enthalten.
ATE155345T1 (de) Gegengift immunsera
ATE192163T1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
IT1254147B (it) Metodo di rivelazione di marcatori tumorali.
EP0351244A3 (en) Antibodies and methods for immunochemical assay using them

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 677111

Country of ref document: ES